National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI

Featured Clinical Trials

Cancer Studies Highlighted in the NCI Cancer Bulletin
< Back to Main

Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Search by Cancer Type
Breast Cancer

Colon and Rectal Cancer

Lung Cancer

Prostate Cancer

More Featured Trials
Search Featured Trials

    Search  
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
Restructuring the NCI Clinical Trials Enterprise

Clinical Trials Reporting Program

Coordinating Center for Clinical Trials

States Requiring Coverage of Clinical Trial Costs
You CAN Quit Smoking Now!
Related Pages
Search for Clinical Trials
NCI's PDQ® Cancer Clinical Trials Registry.

Multiple Myeloma/Other Plasma Cell Neoplasms
NCI's gateway for information about multiple myeloma and other plasma cell neoplasms.
Multiple Myeloma/Plasma Cell Neoplasms - Featured Clinical Trials

The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:

1.  Lenalidomide Maintenance Therapy for Multiple Myeloma
(Posted: 02/24/2009) - In this trial, researchers are exploring whether maintenance therapy with lenalidomide after single autologous stem cell transplantation can slow or prevent the return of multiple myeloma in patients who have undergone induction therapy.

2.  Studying Immune System Reconstitution Following Unrelated Donor Transplantation and Graft-Versus-Host-Disease Prevention
(Posted: 01/13/2009) - Patients with high-risk, advanced hematologic malignancies will undergo induction chemotherapy, reduced-intensity immune-depleting chemotherapy, and allogeneic stem cell transplantation from a matched, unrelated donor, followed by graft-versus-host disease prevention.

3.  New Drugs for Multiple Myeloma Consolidation Therapy
(Posted: 07/08/2008) - In this trial, newly diagnosed multiple myeloma patients who have undergone induction therapy will be treated with consolidation therapy consisting of dexamethasone and the drug bortezomib, and some will also be randomly assigned to receive a third drug called lenalidomide.

4.  Studying Chronic Graft-versus-Host Disease
(Posted: 07/18/2006) - In this study, researchers are interested in determining the natural history of chronic graft-versus-host disease and assessing biological factors that may predict outcomes associated with it.

5.  Preventing Graft-versus-Host Disease during Hematologic Cancer Treatment
(Posted: 05/31/2005) - Researchers are investigating whether an immunosuppressive drug, sirolimus, can work with cyclosporine to prevent graft-versus-host disease (GVHD) more effectively than cyclosporine alone following allogeneic hematopoietic stem cell transplantation.
1 2   Next >

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov